Leerink Partners reissued their market perform rating on shares of Enhabit (NYSE:EHAB – Free Report) in a research note released on Tuesday,Benzinga reports. Leerink Partners currently has a $8.00 price target on the stock, down from their previous price target of $8.50.
Enhabit Trading Down 0.6 %
EHAB stock opened at $7.41 on Tuesday. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit has a 52-week low of $6.85 and a 52-week high of $11.74. The company’s 50-day simple moving average is $7.52 and its 200-day simple moving average is $8.42. The firm has a market cap of $372.69 million, a P/E ratio of -3.19 and a beta of 1.84.
Enhabit (NYSE:EHAB – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same period in the previous year, the business posted $0.03 earnings per share. As a group, equities analysts forecast that Enhabit will post 0.25 EPS for the current fiscal year.
Institutional Trading of Enhabit
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Recommended Stories
- Five stocks we like better than Enhabit
- Short Selling: How to Short a Stock
- Oil’s Rally Could Boost These 3 Shipping Stocks
- 3 REITs to Buy and Hold for the Long Term
- Symbotic Is Up Nearly 50% in 3 Months: Why It Can Keep Winning
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- QuantumScape: High-Risk, High-Reward Solid-State Battery Play?
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.